HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Leucine-rich Glioma-inactivated 1 Encephalitis Followed by Isaacs Syndrome: Alternating Presence of Pathogenic Autoantibodies to Leucine-rich Glioma-inactivated 1 and Contactin-associated Protein-like 2.

Abstract
The coexistence of leucine-rich glioma-inactivated 1 (LGI1) and contactin-associated protein-like 2 (CASPR2) autoantibodies in the same individual is surprisingly often observed. We herein report the first case of LGI1 encephalitis followed by Isaacs syndrome in which LGI1 and CASPR2 antibodies in the serum and cerebrospinal fluid (CSF) were measured during the entire disease course. After the resolution of limbic encephalitis, LGI1 antibodies disappeared from the CSF simultaneously with the appearance of CASPR2 antibodies in the serum. The alternating presence of these pathogenic autoantibodies along with the clinical and phenotypic alternations suggested that LGI1 encephalitis was associated with CASPR2 autoantibody production in the peripheral tissue, leading to CASPR2-associated Isaacs syndrome.
AuthorsAki Murayama, Keizo Sugaya, Makoto Hara, Tomoya Kawazoe, Shinsuke Tobisawa, Hideto Nakajima, Kazushi Takahashi
JournalInternal medicine (Tokyo, Japan) (Intern Med) Vol. 62 Issue 11 Pg. 1659-1663 (Jun 01 2023) ISSN: 1349-7235 [Electronic] Japan
PMID36223927 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Autoantibodies
  • Leucine
  • Intracellular Signaling Peptides and Proteins
  • Contactins
Topics
  • Humans
  • Autoantibodies
  • Leucine
  • Isaacs Syndrome (complications)
  • Intracellular Signaling Peptides and Proteins
  • Encephalitis (diagnosis, complications)
  • Limbic Encephalitis (complications)
  • Contactins

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: